

Case 2. 김 O 숙 (F/53)

C.C> 발열 (onset : 2주 전)

P. I>

이전에는 건강하였던 환자로 내원 3주 전 8일간 터키로 여행을 다녀옴. 귀국 당일부터 fever, chill, cough, purulent sputum 발생하여 귀국 다음날 인근 병원 방문하여 감기로 약 복용하였으나 호전 없어 4일 간 입원 치료 시행함. 그러나 38도 이상의 fever, night sweating 지속되어 건국대 병원으로 전원 되어 6일간 IV antibiotics 투여 받았음. Cough, purulent sputum 은 호전 추세였으나 발열 지속되어 본원 응급실 내원함.

PMHx>

DM/HTN/TB/Liver disease (-/-/+/-) : TB lymphadenitis (30YA)

Social Hx>

Non-smoker, alcohol (-)

Drug History>

Omega 3, Vitamin 제|제|

Systemic review>

G/W (+) E/F (-) Wt loss (-)

F/C (+/+)
C/S/R (+/+/-) Sore throat (+)

Chest pain (-) Dyspnea (-) Orthopnea (-) Palpitation (-)

Abdominal Pain (-) A/N/V/D/C (-/-/-/-/-) H/M/H (-/-/-)

Back pain (-) Urinary Sx (-)

Physical Examination>

Initial V/S 117/61 mmHg – 81/min- 20/min- 36.8'C

(after 4hr, 137/63 mmHg – 102/min – 20/min- 39.1'C)

G/A> acute ill-looking, alert, oriented

HEENT>not anemic, anicteric

L/R (++) , PI (-), PTH (-/-), not dehydrated tongue

V/E (-/-), Neck LNE (-/-)

Chest > symmetric expansion without retraction

BLLF inspiratory crackle

RHB without murmur

Abdomen> Soft & flat

NABS, T/RT (-/-)

L/S/K (-/-/-)

Back & Ext.> CVAT (-/-) P/C/C (-/-/-)

Initial Lab finding>

CBC 19200 – 10.3 – 362K (seg 88.9%) BUN/Cr 5/0.6 mg/dL

T. Bil 0.9 mg/dL ALP 142 (30~115) IU/L AST/ALT 60/35 (0~40) IU/L

Glucose 125 mg/dL Alb 2.5 (3.3~5.2) g/dL CRP 13.55 (0~0.5) mg/dL

ABGA 7.495 – 32.9 – 81.8 – 26.6 – 97.1%

Sputum culture & Blood culture (-), Sputum AFB smear (-)

Legionella urinary Ag (-) Pnuemococcal urinary Ag (-)

CXR : Bilateral basal lung infiltration

Initial Assessment>

#1. Travel related infection

r/o post-travel Legionella pneumonia

r/o Mediterranean spotted fever

#2. r/o CAP

#3. r/o hidden malignancy


Initial Plan>

**#1. #2. doxycycline, levofloxacin start
serology check**

#3. consider VATS

Hospital Course >


| HD 1 | HD 2 | HD 3 |
|------|------|------|
|------|------|------|



Doxycycline

Levofloxacin


Hospital Course >



Hospital Course >

| HD 8 | HD 9 | HD 10 | HD 11 |
|------|------|-------|-------|
|------|------|-------|-------|

| 2010-04-20(SUB) | 2010-04-21(SUB) | 2010-04-22(SUB) | 2010-04-23(SUB) |
|-----------------|-----------------|-----------------|-----------------|
|-----------------|-----------------|-----------------|-----------------|




Doxycycline



- BAL resp. virus PCR : human coronavirus OC43/HKU1 positive
- Cytospin: RBC 10 WBC 554 (seg 8%, lympho 41%)

Hospital Course>



- 퇴원 후 외래에서 확인한 sputum AFB culture 1쌍과 BAL 검체로 시행한 AFB culture 에서 M. Tuberculosis 가 동정 되었음. (약 3 주 후)

- Mild cough 이외 다른 증상 및 검사 소견 모두 호전되어 퇴원함.
- CBC 12290 – 12.1 – 678 (seg 75.2%), CRP 1.52

Clinical Course >

fever



cough, purulent sputum



1st wk

2nd wk

3rd wk

4th wk



↑
터키 여행

↑
발열, 기침 등
의 증상 발생

↑
인근 병원 입원하여
IV moxifloxacin 4일
투여받음.

↑
건국대 병원 입원하여 항생제 치료
받음.

Tazocin+azithromycin
Aztreonam+vancomycin

↑
본원 내원하여
Doxycycline 8 일
Levofloxacin 3일 투여함.

Human Coronaviruses (HCoV)

- enveloped RNA viruses
- the family *Coronaviridae*, genus *coronavirus*
- **HCoV-229E**, **HCoV-OC43** : since the mid-1960s, the cause of common cold
- SARS-CoV : affected > 8000 people with 750 deaths in 2002 and 2003
- **HCoV-NL63** : from a 7month-old infant in Netherlands, 2004
- **HCoV-HKU1** : from an adult who had chronic pulmonary disease in Hong Kong, 2005

Diagnosis of viral pneumonia

1. Viral culture

- Gold standard
- Limitations : lower sensitivity
 - ✓ shedding low titers of viruses for a short period from adults with CAP
 - ✓ thermolabile
 - ✓ take between 3 and 14 days to yield results
 - ✓ require specific technical expertise, labor-intensive, expensive
 - ✓ Human novel coronaviruses (NL63, HKU1) grow poorly in viral cultures.

Diagnosis of viral pneumonia

2. Rapid viral antigen detection

- by immunofluorescence or enzyme immunoassay
- Limitations : lower sensitivity
 - ✓ require relatively higher viral load
 - ✓ lack of reagents (rhinovirus, coronavirus, bocavirus)
 - ✓ lower sensitivity in detecting dual infections

3. Serology

- Single serum Ig G antibody titer is not useful.
- detection of Ig M in acute-phase serum
- Demonstration of a more than four-fold increase in virus-specific Ig G
 - ✓ most reliable
 - ✓ retrospective nature

Diagnosis of viral pneumonia

4. Nucleic acid amplification test

- Improved sensitivity and specificity
- Very rapid results compared with conventional methods
- Multiplex PCR : simultaneously detect a large number of viral agents using a single test

Incidence of viral community-acquired pneumonia

| Population | Cause | Clinical findings | Reference |
|---|--|---|---|
| Consecutive immunocompetent patients admitted to hospital with CAP (N=193) | Overall microbiologic diagnosis 39%; bacterial 20%; viral 15%; mixed 8% (coronavirus OC43, 2%) | Older and more frail; more heart disease; less chest pain; less leukocytosis | Johnstone <i>et al.</i> Chest 2008;134 |
| Consecutive patients admitted to hospital with CAP (N=225) | Overall microbiologic diagnosis 58%; bacterial 48%; viral 30%; mixed 15% (coronavirus OC43 & 229E, 1%) | More myalgia; fewer rigors; fewer smokers; fewer neutrophils in nonrhinovirus infection | Jennings <i>et al.</i> Thorax 2008;63 |
| Consecutive immunocompetent and immunosuppressed patients admitted to hospital with CAP (N=198) | Overall microbiologic diagnosis 57%; bacterial 33%; viral 13%; mixed 10% (coronavirus, 2%) | Fewer leukocytosis; less CRP | Marcos <i>et al.</i> Antivir Ther 2006;11 |
| Consecutive patients admitted to hospital with CAP (N=92); with CAP not hospitalized (N=13) | Overall microbiologic diagnosis 76%; bacterial 44%; viral 50%; mixed 27% (coronavirus OC43 & 229E, 14%) | 87% of patients more than 60 years of age | Templeton <i>et al.</i> Clin Infect Dis 2005;41 |

Clinical features of coronavirus pneumonia

| Characteristic | Description or value for patient ^b : | | | | | |
|---|--|---|------------------------------------|--|--|-----------------------|
| | 1 | 2 | 3 | 4 | 5 | 6 |
| Sex/age (yr) ^a | F/2 | F/7 | M/84 | M/3 | M/87 | F/4 |
| Ethnic origin | Chinese | Chinese | Chinese | Chinese | Chinese | Chinese |
| Underlying condition(s) | | Prematurity, cerebral palsy, epilepsy | COPD, old PTB, IHD, BPH, ex-smoker | Recurrent febrile exanthema, SMA carrier | MVP, AF, HT, hypercholesterolemia, ex-smoker | Febrile convulsion |
| Presenting symptoms | | | | | | |
| Fever | + | + | + | + | + | + |
| Chills | | | + | + | + | |
| Rigor | | | + | + | + | |
| Cough | | | + | | + | + |
| Sputum | | | + | | + | |
| Dyspnea | | | + | | | |
| Rhinorrhea | + | + | + | + | | |
| Vomiting | | | | | + | + |
| Convulsion | + | + | | | | + |
| Other symptom(s) | Diarrhea | Skin rash | Myalgia | Skin rash, joint swelling | | Abdominal pain |
| Physical examination finding(s) | Congested throat, shotty generalized lymphadenopathy | Generalized maculopapular rash, shotty cervical lymphadenopathy | | Limb and joint swelling, generalized rash, shotty cervical lymphadenopathy | Bilateral basal crackles | Congested throat |
| Chest radiograph finding(s) | Not taken | Clear | Old tuberculosis | Not taken | Bilateral lower-zone haziness | Clear |
| Diagnosis | URTI, febrile seizure | URTI, epilepsy | URTI | URTI, angioedema | Pneumonia | URTI, febrile seizure |
| Duration of hospitalization (no. of days) | 3 | 5 | 7 | 2 | 5 | 3 |

Clinical features of coronavirus pneumonia

Table 3 Characteristics of patients with community-acquired pneumonia associated with specific respiratory viruses

| | Aetiological agent | | | | | | |
|--|------------------------|-------------------------|------------------------|-----------------|------------------------|--------------------------------|------------------------|
| | Rhinovirus (n = 31) | Influenza A (n = 23) | Influenza B (n = 6) | RSV (n = 12) | Adenovirus (n = 11) | Parainfluenza virus (n = 6) | Coronavirus (n = 6) |
| Male | 15 (48) | 15 (65) | 2 (33) | 8 (67) | 6 (55) | 3 (50) | 4 (67) |
| Age (years) (median (IQR)) | 66 (42–78) | 66 (55–76) | 72 (68–83) | 79 (70–81) | 51 (30–71) | 81 (73–86) | 71 (55–78) |
| Duration symptoms (days) (median (IQR)) | 7 (3–7) | 7 (3–21) | 6 (4–14) | 6 (4–18) | 3 (2–7) | 6 (4–7) | 6 (4–14) |
| Symptoms | | | | | | | |
| Cough | 29/31 (94) | 21/22 (96) | 5/6 (83) | 12/12 (100) | 9/11 (82) | 6/6 (100) | 6/6 (100) |
| Sputum | 23/31 (74) | 16/22 (73) | 4/6 (67) | 10/12 (83) | 8/11 (73) | 2/5 (40) | 4/6 (67) |
| Pleuritic pain | 18/31 (58) | 8/23 (35) | 3/6 (50) | 4/12 (33) | 6/10 (60) | 2/5 (40) | 4/6 (67) |
| Rigors | 14/29 (48) | 5/11 (46) | 1/3 (33) | 2/8 (25) | 1/4 (25) | 2/3 (67) | 2/2 (100) |
| Lethargy | 26/30 (87) | 15/15 (100) | 4/4 (100) | 7/9 (78) | 5/6 (83) | 2/2 (100) | 3/3 (100) |
| Anorexia | 23/30 (77) | 13/14 (93) | 3/3 (100) | 6/9 (67) | 6/6 (100) | 0/2 (0) | 2/2 (100) |
| Diarrhoea | 5/30 (17) | 5/12 (42) | 3/4 (75) | 4/8 (50) | 2/6 (33) | 0/2 (0) | – |
| Headache | 12/29 (41) | 5/9 (56) | 1/2 (50) | 1/7 (14) | 1/4 (25) | 0/2 (0) | – |
| Myalgia | 7/27 (26) | 5/10 (50) | 2/2 (100) | 2/7 (29) | 2/5 (40) | 0/2 (0) | – |
| Any comorbidity | 18/31 (58) | 13/23 (57) | 3/6 (50) | 10/12 (83) | 7/11 (64) | 3/6 (50) | 4/6 (67) |
| COPD | 6/31 (19) | 8/23 (35) | 1/6 (17) | 4/12 (33) | 3/11 (27) | 2/6 (33) | 3/6 (50) |
| Asthma | 8/31 (26) | 3/23 (13) | 0/6 (0) | 1/12 (8) | 3/11 (27) | 0/6 (0) | 1/6 (17) |
| Cardiac failure | 2/31 (7) | 3/23 (13) | 1/6 (17) | 5/12 (42) | 3/11 (27) | 2/6 (33) | 0/6 (0) |
| Diabetes | 3/31 (10) | 3/23 (13) | 1/6 (17) | 6/12 (50) | 1/11 (9) | 0/6 (0) | 1/6 (17) |
| Cerebrovascular disease | 4/31 (13) | 3/23 (13) | 0/6 (0) | 5/12 (42) | 1/11 (9) | 2/6 (33) | 0/6 (0) |
| Renal disease | 1/31 (3) | 1/23 (4) | 1/6 (17) | 1/12 (8) | 1/11 (9) | 0/6 (0) | 0/6 (0) |
| Current smoker | 7/31 (23) | 7/23 (30) | 1/6 (17) | 1/12 (8) | 4/11 (36) | 1/6 (17) | 0/6 (0) |
| Influenza vaccine within 1 year | 16/31 (52) | 7/23 (30) | 2/5 (40) | 8/12 (67) | 5/11 (46) | 5/6 (83) | 2/6 (33) |
| CURBage >2 | 7/31 (23) | 2/23 (9) | 1/6 (17) | 4/12 (33) | 3/11 (27) | 3/6 (50) | 2/6 (33) |
| PSI class IV and V | 12/31 (39) | 15/23 (65) | 3/6 (50) | 9/12 (75) | 4/11 (36) | 5/6 (83) | 3/6 (50) |

Clinical features of coronavirus pneumonia

| Parameter | Value for patients infected with: | | | |
|--|-----------------------------------|------------|--------------------|------------|
| | CoV-HKU1 | HCoV-NL63 | HCoV-OC43 | HCoV-229E |
| Total no. of patients | 13 | 17 | 53 | 13 |
| Male-to-female ratio | 8:5 | 8:9 | 28:25 | 1:3 |
| Age | | | | |
| Range | 19 mo–87 yr | 6 mo–86 yr | 1 mo–88 yr | 2 yr–75 yr |
| Median (yr) | 4 | 2 | 9 | 8.5 |
| Duration of fever (days) | | | | |
| Range | 1–4 | 1–7 | 1–8 | 1–4 |
| Median | 1 | 1 | 1 | 2.5 |
| Duration of hospitalization (days) | | | | |
| Range | 2–7 | 1–9 | 1–20 | 3–14 |
| Median | 3 | 3 | 3 | 3 |
| No. (%) of patients with underlying diseases | 8 (62) | 10 (59) | 34 (64) | 2 (50) |
| No. (%) of patients with diagnosis of ^a : | | | | |
| URTI ^c | 11 (85) | 12 (71) | 41 (77) | 2 (50) |
| Asthma/COPD exacerbation ^c | 1 (8) | 2 (12) | 4 (8) | 0 (0) |
| Acute bronchiolitis | 1 (8) | 1 (6) | 3 (6) | 0 (0) |
| Pneumonia | 1 (8) | 3 (18) | 8 (15) | 2 (50) |
| Croup | 0 (0) | 2 (12) | 0 (0) | 0 (0) |
| Febrile convulsion | 5 (38) ^b | 3 (18) | 3 (6) ^b | 0 (0) |
| Breakthrough seizure | 2 (15) ^b | 1 (6) | 0 (0) ^b | 0 (0) |
| Aseptic meningitis | 0 (0) | 0 (0) | 1 (2) | 0 (0) |
| Kawasaki disease | 0 (0) | 0 (0) | 1 (2) | 0 (0) |
| No. (%) of patients who died | 0 (0) | 0 (0) | 1 (2) | 0 (0) |

Table 2. Epidemiological, clinical, and radiological characteristics of patients with community-acquired pneumonia associated with coronavirus HKU1. (N=418)


| Characteristic | Patient | | | | | | | | | |
|---|----------------------|--|--------------------------------------|----------------------|---|----------------------|---|----------------------|---|---|
| | 1 | 2 | 3 | 4 | 5 [19] | 6 | 7 | 8 | 9 | 10 |
| Month/year | Mar/2003 | Apr/2003 | May/2003 | Jan/2004 | Jan/2004 | Jan/2004 | Jan/2004 | Jan/2004 | Mar/2004 | Mar/2004 |
| Sex/age, years | F/35 | M/66 | M/13 | M/75 | M/71 | F/96 | M/78 | M/68 | F/83 | M/72 |
| Ethnic origin | Chinese | Arabian | Chinese | Chinese | Chinese | Chinese | Chinese | Chinese | Chinese | Chinese |
| Underlying disease(s) | – | Diabetes mellitus, old myocardial infarction, gastric lymphoma | Asthma, situs inversus, dextrocardia | Hypertension | Chronic obstructive airway disease, hyperlipidemia, abdominal aortic aneurysm | Hypertension | Chronic obstructive airway disease, diabetes mellitus | – | Chronic obstructive airway disease, parathyroid adenoma, dementia | Prostate carcinoma, cerebrovascular accident, diabetes mellitus |
| History of travel within 2 weeks of disease onset | – | – | Shenzhen, China | Guangdong, China | Shenzhen, China | – | – | Guangdong, China | – | – |
| History of smoking | – | – | – | + | + | – | + | – | + | + |
| Clinical feature | | | | | | | | | | |
| Fever | + | – | + | – | + | + | + | + | + | + |
| Chills | – | – | – | – | + | – | – | – | – | – |
| Rigor | – | – | – | – | – | – | – | – | – | – |
| Myalgia | – | – | – | – | – | – | – | – | – | – |
| Headache | – | – | – | – | + | – | – | – | – | – |
| Cough | + | – | + | + | + | – | + | + | – | + |
| Sputum production | – | – | + | + | + | – | + | + | – | + |
| Dyspnea | – | + | – | + | – | – | + | + | + | + |
| Pleurisy | – | – | – | – | – | – | – | – | – | – |
| Rhinorrhea | – | – | – | – | + | – | – | – | – | – |
| Sore throat | + | – | – | – | + | – | – | – | – | – |
| Oxygen saturation level on room air, % | 99 | 83 | 100 | 99 | 99 | 97 | 97 | 95 | 99 | 88 |
| Chest radiograph features | RLZ airspace shadows | Bilateral airspace shadows | LMZ and LLZ airspace shadows | LLZ airspace shadows | LLZ airspace shadows | RLZ airspace shadows | LLZ airspace shadows | RMZ airspace shadows | RLZ airspace shadows | Bilateral airspace shadows |
| Outcome | Survived | Died | Survived | Survived | Survived | Survived | Survived | Survived | Survived | Died |
| Duration of hospitalization, no. of days | 2 | Died on day 12 | 3 | 7 | 5 | 7 | 13 | 5 | 6 | Died on day 6 |

NOTE. +, present; –, absent; LLZ, left lower zone; LMZ, left middle zone; LUZ, left upper zone; RLZ, right lower zone; RMZ, right middle zone; RUZ, right upper zone.

Table 4. Comparison of clinical, laboratory, and radiological characteristics of patients who survived and those who died of coronavirus HKU1-associated pneumonia.

| Characteristic | Outcome ^a | | P |
|---|----------------------|-----------------|-------------------|
| | Survived (n = 8) | Died (n = 2) | |
| Sex, M:F | 5:3 | 2:0 | 1.00 |
| Age, years | 73 | 69 | .60 |
| Underlying diseases | 6 | 2 | .45 |
| History of travel within 2 weeks of disease onset | 4 | 0 | .24 |
| History of smoking | 4 | 1 | 1.00 |
| Clinical features | | | |
| Fever | 7 | 1 | .26 |
| Cough | 6 | 1 | .51 |
| Sputum production | 5 | 1 | .76 |
| Dyspnea | 4 | 2 | .22 |
| Rhinorrhea | 1 | 0 | .62 |
| Sore throat | 2 | 0 | .45 |
| Hematological feature | | | |
| Hemoglobin concentration, g/dL | 13.4 | 9 | .04 ^b |
| Leukocyte count, ×10 ⁹ leukocytes/L | 9.7 | 7.85 | .43 |
| Neutrophil count, ×10 ⁹ neutrophils/L | 7.4 | 6.9 | .79 |
| Lymphocyte count, ×10 ⁹ lymphocytes/L | 1.35 | 0.55 | .15 |
| Monocyte count, ×10 ⁹ monocytes/L | 0.7 | 0.3 | .04 ^b |
| Platelet count, ×10 ⁹ platelets/L | 292 | 200.5 | .79 |
| Serum biochemical feature | | | |
| Sodium concentration, mmol/L | 137.5 | 134 | .11 |
| Potassium concentration, mmol/L | 3.9 | 4.5 | .06 |
| Creatinine concentration, μmol/L | 79 | 76.5 | .69 |
| Urea concentration, mmol/L | 4.6 | 10.75 | .19 |
| Albumin concentration, g/L | 38.5 | 26 | .04 ^b |
| Globulin concentration, g/L | 30 | 30 | 1.00 |
| Bilirubin concentration, μmol/L | 10 | 30.5 | .79 |
| ALT concentration, U/L | 16.5 | 30.5 | .36 |
| Alkaline phosphatase concentration, U/L | 86 | 190.5 | .07 |
| Oxygen saturation level on room air, % | 99 | 85.5 | .03 ^b |
| Radiological feature | | | |
| Bilateral involvement | 0 | 2 | .003 ^b |
| No. of zones involved | 1 | 6 | .01 ^b |

Clinical features of coronavirus pneumonia



30 patients who tested positive for human coronavirus OC43 by RT-PCR hybridization, February and March 2001, Lower Normandy, France.

Clinical value of a positive result by respiratory virus PCR


- HCoV 229E and HCoV OC43 were not found by RT-PCR of nasopharyngeal aspirated from children without respiratory symptoms in Finland.

J Med Virol 2002;66:417-20

- 2 (15.4%) of 13 nasopharyngeal swabs from patients with pneumonia : positive RT-PCR for HCoV.
- HCoV RNA was detected in only 1 (0.4%) of 243 nasopharyngeal swabs from patients without symptoms of respiratory tract infection.

J Infect Dis 189;652-7

Clinical value of a positive result by respiratory virus PCR



Clinical value of a positive result by respiratory virus PCR

- HCoV-positive finding by RT-PCR in a specimen from a symptomatic patient might have diagnostic significance.